Jeffrey W. Dunn, a director at SI-BONE, Inc. (NASDAQ: SIBN), executed a sale of 3,575 shares of the company’s common stock on June 5, 2026. The transaction resulted in a total value of $54,505. The shares were divested at a weighted average price of $15.2462 per share, with execution prices ranging between $15.085 and $15.42. The stock was trading at $14.97 at the time of reporting, marking a 7.93% gain over the preceding week.
This specific sale was classified as a mandatory transaction required to satisfy tax withholding obligations associated with the vesting of restricted stock units. The transaction did not represent a discretionary decision by Mr. Dunn. Prior to this sale, on June 4, 2026, Mr. Dunn acquired 10,957 shares of SI-BONE common stock. These shares were acquired as a result of the settlement of restricted stock units granted to him. Each unit represented a contingent right to receive one share of the company’s common stock. The vesting of these shares is contingent upon the earlier of the next annual general meeting of stockholders or one year from the vesting commencement date, subject to Mr. Dunn’s continuous service as a member of the Board of Directors.
Following these transactions, Mr. Dunn’s direct holdings in SI-BONE common stock total 16,057 shares. Additionally, he holds an indirect position of 81,073 shares through The Jeffrey W. Dunn Living Trust, dated May 17, 2012. SI-BONE, Inc. is a medical device company with a market capitalization of $664.8 million. Analyst price targets for the stock range from $18 to $32. According to InvestingPro analysis, the stock appears overvalued at current levels. The platform offers additional ProTips for deeper insight into SIBN’s investment potential.
In other recent news, SI-BONE, Inc. reported its first-quarter 2026 financial results. The company revealed a narrower-than-expected net loss and strong revenue growth. The company posted an earnings per share (EPS) of -$0.10, outperforming the forecast of -$0.19. Revenue came in at $52.6 million, slightly below the anticipated $52.85 million. Despite this, SI-BONE raised its revenue guidance, roughly aligning with the first-quarter beat at the midpoint, and increased its gross margin guidance by 100 basis points due to an improved average selling price mix.
Additionally, Truist Securities adjusted its price target for SI-BONE to $18 from $20 while maintaining a Buy rating. The revision reflects conservative guidance despite the company’s positive earnings performance. These developments indicate a mixed outlook from analysts, balancing the company’s strong quarterly results with adjusted expectations for the future.